2,200 Shares in Hinge Health Inc. $HNGE Purchased by Mark Sheptoff Financial Planning LLC

Mark Sheptoff Financial Planning LLC purchased a new stake in Hinge Health Inc. (NYSE:HNGE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,200 shares of the company’s stock, valued at approximately $114,000.

A number of other large investors have also recently modified their holdings of the business. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Hinge Health during the second quarter worth about $828,000. Strategic Blueprint LLC purchased a new position in Hinge Health in the 2nd quarter worth approximately $346,000. FNY Investment Advisers LLC bought a new stake in shares of Hinge Health during the 2nd quarter worth $310,000. Finally, Emerald Advisers LLC purchased a new position in Hinge Health in the second quarter worth $108,000.

Hinge Health Price Performance

Shares of HNGE opened at $44.43 on Friday. Hinge Health Inc. has a twelve month low of $33.42 and a twelve month high of $62.18. The firm’s fifty day moving average price is $52.43.

Hinge Health (NYSE:HNGE) last posted its earnings results on Tuesday, November 4th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.18. The firm had revenue of $154.21 million for the quarter, compared to analysts’ expectations of $142.44 million. The company’s quarterly revenue was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Citizens Jmp began coverage on Hinge Health in a report on Monday, July 14th. They issued a “strong-buy” rating and a $58.00 price objective for the company. Canaccord Genuity Group upped their price objective on shares of Hinge Health from $61.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday. KeyCorp increased their target price on shares of Hinge Health from $45.00 to $60.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hinge Health in a research note on Wednesday, October 8th. Finally, Robert W. Baird assumed coverage on Hinge Health in a report on Friday, September 5th. They issued a “neutral” rating and a $56.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $59.93.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.